Modality
Vaccine
MOA
Anti-Tau
Target
TNFα
Pathway
Lipid Met
Gastric Ca
Development Pipeline
Preclinical
~Jul 2018
→ ~Oct 2019
Phase 1
Jan 2020
→ Nov 2028
Phase 1Current
NCT08747801
1,105 pts·Gastric Ca
2020-01→2028-11·Recruiting
1,105 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-11-202.6y awayInterim· Gastric Ca
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P1
Recruit…
Catalysts
Interim
2028-11-20 · 2.6y away
Gastric Ca
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08747801 | Phase 1 | Gastric Ca | Recruiting | 1105 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| NVS-5439 | Novartis | Preclinical | BET | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| Sovanaritide | Argenx | Phase 3 | TNFα | |
| BGN-3305 | BeiGene | Phase 2 | BCMA | |
| Sovarasimod | Halozyme | Phase 1/2 | WEE1 |